| CLARIO | |
| Type: | Private |
| Location City: | Philadelphia |
| Location Country: | U.S. |
| Key People: | Christopher Fikry, M.D.(CEO)[1] |
| Industry: | Healthcare Clinical Research Pharmaceutical Service Medical Technology |
| Revenue: | $350 million to $400 million (USD) per year |
| Owner: | Privately Owned |
| Num Employees: | 1001 to 5000 employees (2024) |
CLARIO formerly ERT and Bioclinica[2] is a technology company specializing in clinical services and customizable medical devices to biopharmaceutical and healthcare organizations. It offers centralized cardiac safety and respiratory efficacy services in drug development and also collects, analyzes and distributes electronic patient-reported outcomes (ePRO) in multiple modalities across all phases of clinical research.[3]
In 2008 ERT acquired Biosigna, a Munich-based company, which specialized in biomedical signal processing.
In 2009 ERT ended its foray into the electronic data capture (EDC) business as ERT sold its EDC division for approximately $2.025 million of OmniComm shares.[4]
In 2010 ERT acquired the Research Services Division of the CareFusion Corporation. This nearly doubled the company in size and brought a new service line and enhancements to its two current service offerings; Respiratory Services, specializing in centralized spirometry, Multi-Mode ePRO for patient reported outcomes, and enhanced Cardiac Safety Solutions. Along with the acquisition, ERT now has the capability to design and construct their own clinical diagnostic devices from a manufacturing facility in Estenfeld, Germany.[5]
In 2010, the then current CEO of ERT was replaced on an interim basis by Joel Morganroth, M.D.[6] [7] [8]
In 2011 Jeffrey S. Litwin, M.D. was appointed ERT's new president and chief executive officer. Litwin joined ERT in 2000 as senior vice president and chief medical officer and was subsequently promoted in December 2005 to executive vice president and chief medical officer. Dr. Litwin oversaw ERT's global cardiac safety operations for seven years.
On July 3, 2012, ERT announced that Genstar Capital LLC of San Francisco acquired ERT in a take-private transaction valued at approximately $400 million.
In November 2014 ERT acquired eClinical Insights (eCI), a provider of cloud-based clinical trials management software.[9]
On February 27, 2015, ERT acquired PHT Corporation (PHT).[10]
In March 2016 ERT was acquired by Nordic Capital, a private healthcare investment firm for about $1.8 Billion.[11]
In December 2016 ERT acquired Exco InTouch, a provider of patient engagement, data capture and digital health solutions.
In May 2017 ERT acquired ImageIQ, clinical trial biomedical imaging and analysis company.[12]
In September 2017 ERT acquired Biomedical Systems (BMS), a provider of imaging as well as cardiac safety and respiratory data collection solutions.[13]
In December 2017 ERT acquired iCardiac Technologies, a global provider of centralized cardiac safety, respiratory, and electronic clinical outcome assessment (eCOA) solutions that accelerate clinical research.[14]
In June 2020 ERT acquired APDM Wearable Technologies, a next-generation provider of wearables and digital biomarkers.[15]
In December 2020, ERT announced a merger with Bioclinica, a global clinical trial end-point solutions company. Joe Eazor will be the head of the new business.
In November 2021, following ERT and Bioclinica merger, the company renames as Clario.[16]
In April 2024, it was announced Clario had acquired the Leuven, Belgium-headquartered AI medical technology company, ArtiQ.[17]